VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Adenovirus-vectored therapeutic vaccine (Ad-Ii-E1E2E6E7)

Vaccine Information

Vaccine Name: Adenovirus-vectored therapeutic vaccine (Ad-Ii-E1E2E6E7)
Target Pathogen: Cancer
Target Disease: Cancer
Type: Recombinant vector vaccine
Status: Research
Host Species for Licensed Use: Mouse
Host Species as Laboratory Animal Model: Mouse
Antigen: HPV16 antigens: E1, E2, E6, and E7 (Boilesen et al., 2023)
Immunization Route: Intramuscular injection (i.m.)
Description: The vaccine enhances CD8+ and CD4+ T-cell responses, targeting HPV16 proteins effectively. Regulatory CD4+ T cells (Tregs) were increased, potentially modulating therapeutic efficacy. The vaccine induced robust CD8+ T-cell responses, particularly to E1 and E7, and CD4+ responses to E1 and E2. High-affinity binding epitopes (IC50: 0–50 nM) dominate in E1, suggesting its strong immunogenic potential. (E1-specific CD8+ and CD4+ T-cell responses were consistently detected across all mouse models.) The vaccine reduced tumor growth and improved survival in HPV-positive C3 tumor-bearing mice, both as a monotherapy and in combination with cisplatin. No significant CD8+ responses were detected for E2 or E6 in C57BL/6 mice. The Ad-Ii-E1E2E6E7 vaccine outperformed synthetic E6/E7 peptides in terms of tumor control and survival.

Host Response

References

Boilesen et al., 2023: Boilesen DR, Neckermann P, Willert T, MÃ¼ller MD, SchrÃ¶del S, Pertl C, Thirion C, Asbach B, Wagner R, Holst PJ. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 Cancers in Mice. Cancer immunology research. 2023; 11(2); 261-275. [PubMed: 36534088].